Organon Moves into Prevention of Women’s Deaths in Childbirth with Alydia Acquisition
Merck’s women’s health spinoff Organon is expanding into prevention of women’s deaths during childbirth through its acquisition of the medical device company Alydia Health.
Alydia specializes in preventing maternal morbidity and mortality caused by postpartum hemorrhage or abnormal postpartum uterine bleeding.
Alydia’s Jada System is designed to encourage normal contraction of the uterus to stop excessive bleeding after childbirth. The system received 510(k) clearance from the FDA in August 2020.
Organon has completed its acquisition of Alydia Health for $240 million, including a $215 million cash payment.